Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma

Cancer

Volumn 91, Issue 1, 2001, Pages 155-163

  Vaccher, Emanuela ^a   Spina, Michele ^a   Gennaro, Giampiero Di ^a   Talamini, Renato ^a   Nasti, Guglielmo ^a   Schioppa, Ornella ^a   Vultaggio, Giuseppe ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Chemotherapy; Highly active antiretroviral therapy; Human immunodeficiency virus acquired immunodeficiency syndrome related non Hodgkin lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENIPOSIDE; VINCRISTINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035174107     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B     Document Type: Article

References (44)

1. Antiretroviral therapy for HIV infection in 1998
2. Combination therapy for patients with HIV-1 infection: The use of dual nucleoside analogues with protease inhibitors and other agents
3. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
4. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Changing patterns of mortality across Europe in patients infected with HIV-1
7. Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden
8. Clinical management of human immunodeficiency virus-associated non-Hodgkin's lymphoma
9. AIDS oncology
10. Effect of antiretroviral therapy on recent trends in cancers among HIV-infected persons
11. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
12. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: A highly active regimen
13. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
14. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
15. HIV population dynamics in vivo: Implications for genetic variations, pathogenesis, and therapy
16. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
17. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
18. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma
19. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors
20. Report on the EORTC lymphoma trial 20751
21. Superiority of second over first generation chemotherapy in a randomized trial for Stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): The 1980-1985 EORTC trial
22. NCI-sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project
23. Report of the committee on non-Hodgkin's disease classification
24. Expanded European AIDS case definition
25. Diagnosis of hepatitis C
26. Reporting results of cancer treatment
27. Nonparametric estimation from incomplete observations
28. The importance of dose intensity in the outcome of chemotherapy
29. The use of new antiretroviral therapy in combination with chemotherapy
30. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex
31. Phase I AIDS Clinical Trials Group (075) study of Adriamycin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
32. Antiretroviral therapy
33. Pharmacology of cancer chemotherapy - Antimicrotubule agents
34. HIV-protease inhibitors
35. Interaction of anti-HIV protease inhibitors with the mulidrug transporter P-glycoprotein (P-gp) in human cultured cells
36. Clinical studies with modulators of multidrug resistance
37. Pilot trial of saquinavir and nucleoside analogues plus infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma [abstract]
38. Chemotherapy for HIV-associated non-Hodgkin lymphoma (HIV-NHL) in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity [abstract]
39. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy
40. Dose-adjusted EPOCH chemotherapy (CT) in previously untreated HIV-associated non-Hodgkin's lymphoma (HIV-NHL): Preliminary report of efficacy, immune reconstitution, and HIV control following therapy [abstract]
41. Reconstitution of long-term T helper cell function after zidovudine therapy in human immu-nodeficiency virus-infected patients
42. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents
43. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
44. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy